Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo; Andre C. Schuh; Eytan M. Stein; Pau Montesinos Fernandez; Andrew Wei; Stephane De Botton; Amer M. Zeidan; Amir T. Fathi; Lynn Quek; Hagop M. Kantarjian; Mark G. Frattini; Frederik Lersch; Jing Gong; Aleksandra Franovic; Kyle MacBeth; Paresh Vyas; Hartmut Dohner

doi:10.1182/blood-2019-130362

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

Courtney D. DiNardo, Andre C. Schuh, Eytan M. Stein, Pau Montesinos Fernandez, Andrew Wei, Stephane De Botton, Amer M. Zeidan, Amir T. Fathi, Lynn Quek, Hagop M. Kantarjian, Mark G. Frattini, Frederik Lersch, Jing Gong, Aleksandra Franovic, Kyle MacBeth, Paresh Vyas, Hartmut Dohner

Comprehensive Cancer Centre

Research output: Contribution to journal › Meeting Abstract › peer-review

Original language	English
Journal	Blood
Volume	134
DOIs	https://doi.org/10.1182/blood-2019-130362
Publication status	Published - 13 Nov 2019

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1182/blood-2019-130362

Cite this

DiNardo, C. D., Schuh, A. C., Stein, E. M., Fernandez, P. M., Wei, A., De Botton, S., Zeidan, A. M., Fathi, A. T., Quek, L., Kantarjian, H. M., Frattini, M. G., Lersch, F., Gong, J., Franovic, A., MacBeth, K., Vyas, P., & Dohner, H. (2019). Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study. Blood, 134. https://doi.org/10.1182/blood-2019-130362

DiNardo, Courtney D. ; Schuh, Andre C. ; Stein, Eytan M. et al. / Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study. In: Blood. 2019 ; Vol. 134.

@article{33f9b7d2f20146c6b5d430be83bcf22b,

title = "Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study",

author = "DiNardo, {Courtney D.} and Schuh, {Andre C.} and Stein, {Eytan M.} and Fernandez, {Pau Montesinos} and Andrew Wei and {De Botton}, Stephane and Zeidan, {Amer M.} and Fathi, {Amir T.} and Lynn Quek and Kantarjian, {Hagop M.} and Frattini, {Mark G.} and Frederik Lersch and Jing Gong and Aleksandra Franovic and Kyle MacBeth and Paresh Vyas and Hartmut Dohner",

year = "2019",

month = nov,

day = "13",

doi = "10.1182/blood-2019-130362",

language = "English",

volume = "134",

journal = "Blood",

issn = "0006-4971",

publisher = "American Society of Hematology",

}

DiNardo, CD, Schuh, AC, Stein, EM, Fernandez, PM, Wei, A, De Botton, S, Zeidan, AM, Fathi, AT, Quek, L, Kantarjian, HM, Frattini, MG, Lersch, F, Gong, J, Franovic, A, MacBeth, K, Vyas, P & Dohner, H 2019, 'Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study', Blood, vol. 134. https://doi.org/10.1182/blood-2019-130362

Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study. / DiNardo, Courtney D.; Schuh, Andre C.; Stein, Eytan M. et al.
In: Blood, Vol. 134, 13.11.2019.

Research output: Contribution to journal › Meeting Abstract › peer-review

TY - JOUR

T1 - Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study

AU - DiNardo, Courtney D.

AU - Schuh, Andre C.

AU - Stein, Eytan M.

AU - Fernandez, Pau Montesinos

AU - Wei, Andrew

AU - De Botton, Stephane

AU - Zeidan, Amer M.

AU - Fathi, Amir T.

AU - Quek, Lynn

AU - Kantarjian, Hagop M.

AU - Frattini, Mark G.

AU - Lersch, Frederik

AU - Gong, Jing

AU - Franovic, Aleksandra

AU - MacBeth, Kyle

AU - Vyas, Paresh

AU - Dohner, Hartmut

PY - 2019/11/13

Y1 - 2019/11/13

U2 - 10.1182/blood-2019-130362

DO - 10.1182/blood-2019-130362

M3 - Meeting Abstract

SN - 0006-4971

VL - 134

JO - Blood

JF - Blood

ER -

DiNardo CD, Schuh AC, Stein EM, Fernandez PM, Wei A, De Botton S et al. Enasidenib Plus Azacitidine Significantly Improves Complete Remission and Overall Response Compared with Azacitidine Alone in Patients with Newly Diagnosed Acute Myeloid Leukemia (AML) with Isocitrate Dehydrogenase 2 (IDH2) Mutations: Interim Phase II Results from an Ongoing, Randomized Study. Blood. 2019 Nov 13;134. doi: 10.1182/blood-2019-130362